Q2 2026 ADC Therapeutics SA Earnings Call Transcript
Key Points
- ADC Therapeutics SA (ADCT) reported Q2 2026 net product revenues of $18.6 million, slightly up from $18.1 million in Q2 2025, indicating stable commercial performance for Zynlonta in third-line plus DLBCL.
- The company completed enrollment of 100 patients in the LOTUS-7 trial, with data suggesting the Zynlonta plus glofitamab combination is the most compelling in second-line DLBCL, potentially positioning it as a best-in-class therapy.
- ADC Therapeutics SA (ADCT) plans to submit for breakthrough therapy designation for the LOTUS-7 combination and is exploring a Phase 3 pathway, which could expand Zynlonta's use into earlier lines of therapy.
- The company reduced operating expenses by 22% year-over-year on an adjusted basis and implemented a strategic reorganization expected to save approximately $10 million annually, improving financial efficiency.
- ADC Therapeutics SA (ADCT) ended Q2 2026 with a healthy cash balance of $219.1 million, providing a cash runway at least into 2028 to support key clinical and regulatory activities.
- The company is advancing multiple pipeline opportunities, including updated data for marginal zone lymphoma and follicular lymphoma, with potential for breakthrough designation in MZL, broadening Zynlonta's addressable market.
- The FDA expressed substantial concerns regarding the benefit-risk profile of the LOTUS-5 trial, which met its primary endpoint of progression-free survival, casting uncertainty on the regulatory path for full approval of Zynlonta plus rituximab.
- ADC Therapeutics SA (ADCT) is reassessing the regulatory strategy for LOTUS-5, with no clear timeline for resolution, potentially delaying label expansion into second-line DLBCL.
- The LOTUS-5 trial observed grade 5 infections, primarily bacterial, which were not mitigated by prophylaxis, raising safety concerns that could impact the drug's perception and adoption.
- The company's strategic reorganization included a 17% workforce reduction, which may affect operational capacity and morale, despite cost savings.
- ADC Therapeutics SA (ADCT) faces a competitive and evolving DLBCL landscape, and the delay in LOTUS-5 regulatory progress could allow competitors to gain market share in earlier lines of therapy.
- The company's net loss, while improved, remains significant at $16.6 million for Q2 2026, and the reliance on pipeline success for future growth carries inherent clinical and regulatory risks.
Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Q2 2026 Earnings Conference Call.
(Operator Instructions)
I would now like to turn the conference over to Nicole Riley, Head of Investor Relations and Corporate Communications. Please go ahead.
Thank you, operator. Today, we issued a press release announcing our second quarter 2026 financial results and business updates. This release and the slides we will use in today's presentation are available on the Investors section of the ADC Therapeutics website.
I'm joined on today's call by our Chief Executive Officer, Amit Malik, who will discuss our operational performance and recent business highlights, followed by our Chief Medical Officer, Mohamed Zaki, who will provide clinical and regulatory updates. And lastly, our Chief Financial Officer, Pepe Carmona, who will review our second quarter 2026 financial results. We will then open the call to questions.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
